Abbott has entered a definitive agreement with Piramal Healthcare Ltd. to acquire Piramal’s Healthcare Solutions business (Domestic Formulations), a leader in the Indian branded generics market, for $2.1 billion, plus $400 million annually for the next four years, for a total purchase price of $3.7 billion. The acquisition expands Abbott’s branded generics portfolio. Abbott recently acquired Solvay Pharmaceuticals and created a new stand-alone Established Products Division to focus on expa...